Artica Capsule, Tablet, Syrup
Artica is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids. Artica stimulates the production of proteoglycans and increases sulfate uptake by articular cartilage.
Indicated for the treatment of osteoarthritis of knee, hip, spine, and other locations. Also used as dietary supplement
Artica is also used to associated treatment for these conditions: Arthritis, Backache, Joint Pain, Osteoarthritis (OA), Osteoarthritis of the Knee
|Other Names||Chitosamine, D-Glucosamine, Glucosamina, Glucosamine|
|Weight||10mg, 25mg, 10mg/5ml|
|Type||Capsule, Tablet, Syrup|
|Therapeutic Class||Stimulation of Cartilage formation|
|Manufacturer||Ind Swift Laboratories Ltd, Aci Limited|
|Available Country||India, Bangladesh|
|Last Updated:||June 23, 2021 at 9:14 am|
Table Of contents
500 mg tablet three times daily or as directed by the physician. A single dose of 1500 mg daily may also be effective. Obese individuals may need higher doses, based on body weight.
Safety studies with Artica show no demonstrable toxicity. Rarely occurring side effects like mild & reversible intestinal flatulence are almost like placebo.
Diabetics are advised to monitor blood glucose levels regularly while taking Artica. No special studies were formed in patients with renal and/or hepatic insufficiency. The toxicological and pharmacokinetic profile of the product does not indicate limitations for these patients. However, administration to these patients with severe hepatic or renal insufficiency should be under appropriate medical supervision.
There have been no reports of significant drug interactions ofArtica with antibiotics, antidepressants, antihypertensives, nitrates, antiarrhythmics, anxiolytic, hypoglycaemic agents, anti-secretives.
Food InteractionNo interactions found.
Volume of Distribution
Results of a pharmacokinetic study of 12 healthy volunteers receiving three daily consecutive oral administrations of glucosamine sulfate soluble powder demonstrated glucosamine distribution to extravascular compartments. Human pharmacokinetic data for glucosamine is limited in the literature, however, a large animal model study of horses revealed a mean apparent volume of distribution of 15.4 L/kg. Concentrations of glucosamine ranged from 9-15 microM after an intravenous dose, and 0.3-0.7 microM after nasogastric dosing. These concentrations remained in the range of 0.1-0.7 microM in the majority of horses 12 hours after dosing, suggesting effectiveness of a once-daily dose. In rats and dogs, radioactivity from a C-14 labeled dose of glucosamine is detected in the liver, kidneys, articular cartilage, and other areas.
The estimated half-life for glucosamine is 15 hours after an oral dose. After a bolus intravenous injection of 1005 mg crystalline glucosamine sulfate, the parent drug has an apparent half life of 1.11 hours.
Pregnancy & Breastfeeding use
Women who are pregnant or who could become pregnant should not supplement with glucosamine. Artica has not been studied enough to determine their effects on a developing fetus. And no studies have evaluated the use of Artica during pregnancy or lactation. It should be taken with caution and medical advice during pregnancy and lactation.
There are no known contraindications for Artica. But proven hypersensitivity to Artica is a contraindication.
Should be stored in cool and dry place.